Alumis Inc. (NASDAQ:ALMS - Get Free Report) major shareholder Foresite Labs, Llc acquired 25,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was purchased at an average cost of $4.62 per share, with a total value of $115,500.00. Following the purchase, the insider now owns 4,227,670 shares of the company's stock, valued at $19,531,835.40. The trade was a 0.59% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Foresite Labs, Llc also recently made the following trade(s):
- On Tuesday, May 6th, Foresite Labs, Llc bought 20,000 shares of Alumis stock. The shares were bought at an average price of $4.34 per share, with a total value of $86,800.00.
Alumis Stock Performance
Shares of NASDAQ:ALMS traded up $0.07 during trading on Monday, reaching $5.10. The stock had a trading volume of 59,800 shares, compared to its average volume of 324,203. The business has a fifty day moving average price of $5.43 and a 200-day moving average price of $7.15. Alumis Inc. has a 1-year low of $3.18 and a 1-year high of $13.53.
Analyst Ratings Changes
ALMS has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Alumis in a research report on Wednesday, April 30th. Oppenheimer assumed coverage on shares of Alumis in a research note on Thursday, January 30th. They set an "outperform" rating and a $32.00 price target on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.86.
Read Our Latest Stock Report on ALMS
Institutional Trading of Alumis
Several large investors have recently bought and sold shares of ALMS. Wells Fargo & Company MN increased its position in shares of Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after purchasing an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis during the fourth quarter worth approximately $79,000. Rhumbline Advisers raised its stake in Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after acquiring an additional 2,949 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Alumis in the 4th quarter valued at about $108,000. Finally, XTX Topco Ltd purchased a new position in shares of Alumis during the fourth quarter worth about $129,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Further Reading
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
